DDInter82 DDInter1676
Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Amoxapine {u} (Compound) resembles {v} (Compound) Chlordiazepoxide
Amoxapine {u} (Compound) resembles {v} (Compound) Lorazepam
Amoxapine {u} (Compound) binds {v} (Gene) HTR7
Amoxapine {u} (Compound) upregulates {v} (Gene) MSMO1
Amoxapine {u} (Compound) causes {v} (Side Effect) Flatulence
Amoxapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronabinol
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Amoxapine (Compound) resembles Chlordiazepoxide (Compound)
Amoxapine (Compound) resembles Lorazepam (Compound)
Amoxapine (Compound) binds HTR7 (Gene)
Amoxapine (Compound) upregulates MSMO1 (Gene)
Amoxapine (Compound) causes Flatulence (Side Effect)
Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amoxapine may lead to a major life threatening interaction when taken with Macimorelin
Amoxapine may lead to a major life threatening interaction when taken with Anagrelide